Filing Flows › Comparisons › HUMA vs BEAM
Humacyte vs Beam Therapeutics: HUMA and BEAM compared
Humacyte is the larger company: $406K of revenue in its latest quarter (Q2 2026) against $307K for Beam Therapeutics (Q3 2026). Humacyte is growing faster (+35% against -97% a year earlier).
Where the money goes: HUMA and BEAM
Humacyte (HUMA) · Q2 2026
Humacyte, Q2 2026: revenue $406K (+35% year over year), net loss $36.8M, operating cash flow −$22.1M. The chart follows the revenue to costs, profit and cash.
Beam Therapeutics (BEAM) · Q3 2026
Beam Therapeutics, Q3 2026: revenue $307K (-97% year over year), net loss $134M, operating cash flow −$111M. The chart follows the revenue to costs, profit and cash.
| Humacyte (HUMA) | Beam Therapeutics (BEAM) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q3 2026 |
| Revenue | $406K | $307K |
| Revenue growth, Y/Y | +35% | -97% |
| Operating margin | n/m | n/m |
| Net earnings | −$36.8M | −$134M |
| Operating cash flow | −$22.1M | −$111M |
Questions
Which is bigger, Humacyte or Beam Therapeutics?
Humacyte is the larger company: $406K of revenue in its latest quarter (Q2 2026) against $307K for Beam Therapeutics (Q3 2026).
Is Humacyte or Beam Therapeutics growing faster?
Humacyte is growing faster (+35% against -97% a year earlier).
More: Humacyte earnings · how Humacyte makes money · Beam Therapeutics earnings · how Beam Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 12, 2026; 10-Q filed Nov 3, 2026). Fiscal quarters can end on different dates. Not investment advice.